Japan Discuss Faster AI Processing For Healthcare Sector
Flexibility Required
Executive Summary
As Japan's PMDA reopens discussions on the appropriate regulation of AI in healthcare, a process which has so far focused on diagnostic technologies, some committee members point out the need for a more flexible approach.
You may also be interested in...
Regulating Software As A Medical Device Will Take Paradigm Shift, Former FDA Chief Counsel Says
Sidley Austin partner and former FDA Chief Counsel Jeff Senger told Medtech Insight that the FDA’s software pre-certification program will need to clear manufacturers, as well as software itself.
'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends
The CEO of one the global top-five CROs points out a larger opportunity in decentralized trials that might be a “game changer” in the global pharma industry over the next five years. He also refers to the need to accept new technologies by both clinical trial sites and regulators.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.